The firm is an international venture capital firm focused on investing in clinical-stage healthcare companies. The firm invests primarily in companies advancing therapeutic programs while also considering opportunities in diagnostics, medical devices, and digital health. The firm generally targets companies conducting Phase I or Phase II clinical trials or equivalent stages of development and invests across major healthcare markets.
The firm’s primary focus is therapeutics, although it remains open to diagnostics, medical devices, and digital health opportunities. The firm is generally indication-agnostic but has particular interest in diabetes, pulmonology, ophthalmology, oncology, and other areas with significant unmet medical need. The firm prioritizes companies with meaningful clinical validation and strong translational potential.
From a company and management team perspective, the firm typically participates as a co-investor and generally prefers opportunities that already have a lead investor in place. The firm does not typically require board representation and does not have specific management team requirements, allowing it to work with a broad range of experienced and emerging leadership teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 